Oct. 4 at 6:22 AM
$CCCC A few points from my notes here. Very promising undervalued company here. Tutes own most of the float with about 12% insider owned. For a
$161M MC small cap bio thats really rare.
$223M in cash as of 6/30 to last til 2027. Very low short % here means everyone is bullish. Pfizer collab last week. Price analyst targets all strong: Wells fargo raised price to
$10 9/23. Barclays raised to
$10 9/23. Stephens & Co raised to
$6 from
$3 9/15. Big catalyst coming up 10/20 at American conference on pharmacometrics analyzing cemsidomide clinical data. Somehow price is in the low 2s after all this. Get back above 200 sma at 2.36 first stop. then 200 ema 2.70. Golden cross in September even though it fell below 200. Should be a good accumulation zone down here. So many other high cash rich small caps where the tutes own the float always run, its just when.
